Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7401 to 7450 of 8236 results

  1. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

    NICE guideline
    Discontinued

  2. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  3. Preterm labour and birth - predicting preterm birth

    Discontinued Reference number: GID-NG10384

    NICE guideline
    Discontinued

  4. Preterm labour and birth - timing of cord clamping

    Discontinued Reference number: GID-NG10396

    NICE guideline
    Discontinued

  5. Intrapartum care for healthy women and babies - angle of episiotomy

    Discontinued Reference number: GID-NG10394

    NICE guideline
    Discontinued

  6. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued Reference number: GID-NG10395

    NICE guideline
    Discontinued

  7. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued Reference number: GID-NG10385

    NICE guideline
    Discontinued

  8. Conjunctivitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10166

    Antimicrobial prescribing guideline
    Discontinued

  9. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

    Antimicrobial prescribing guideline
    Discontinued

  10. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

    Antimicrobial prescribing guideline
    Discontinued

  11. Skin abscess: antimicrobial prescribing

    Discontinued Reference number: GID-NG10163

    Antimicrobial prescribing guideline
    Discontinued

  12. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

    NICE guideline
    Discontinued

  13. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  14. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development Reference number: GID-TA11189 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

    Medical technologies guidance
    In development

  17. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  18. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  19. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued Reference number: GID-TAG372

    Technology appraisal guidance
    Discontinued

  20. Prasterone for the treatment of systemic lupus erythematosus [ID392]

    Discontinued Reference number: GID-TAG373

    Technology appraisal guidance
    Discontinued

  21. Thrombophilia [ID393]

    Discontinued Reference number: GID-TAG374

    Technology appraisal guidance
    Discontinued

  22. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued Reference number: GID-TAG375

    Technology appraisal guidance
    Discontinued

  23. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued Reference number: GID-TAG376

    Technology appraisal guidance
    Discontinued

  24. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  25. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

    Technology appraisal guidance
    Discontinued

  26. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  27. Colon cancer (adjuvant) - irinotecan [ID379]

    In development Reference number: GID-TAG380 Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued

  29. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  30. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  31. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  32. Diabetic retinopathy - ruboxistaurin [ID382]

    In development Reference number: GID-TAG386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  34. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development Reference number: GID-TAG388 Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued Reference number: GID-TAG389

    Technology appraisal guidance
    Discontinued

  36. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued

  37. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  38. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

    Technology appraisal guidance
    Discontinued

  39. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

    Technology appraisal guidance
    Discontinued

  40. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  41. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued Reference number: GID-TAG397

    Technology appraisal guidance
    Discontinued

  42. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

    Technology appraisal guidance
    Discontinued

  43. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued Reference number: GID-TAG399

    Technology appraisal guidance
    Discontinued

  44. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

    Technology appraisal guidance
    Discontinued

  45. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  46. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

    Technology appraisal guidance
    Discontinued

  47. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  48. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development Reference number: GID-TA11015 Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development Reference number: GID-TA11014 Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development Reference number: GID-TA10568 Expected publication date: TBC

    Technology appraisal guidance
    In development